Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) from a hold rating to a strong-buy rating in a research note issued to investors on Monday.

KNSA has been the subject of several other reports. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday, April 21st. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Finally, Canaccord Genuity Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.86.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $57.62 on Monday. Kiniksa Pharmaceuticals International has a 1 year low of $24.85 and a 1 year high of $57.72. The firm has a market cap of $4.41 billion, a PE ratio of 64.02 and a beta of 0.17. The company has a 50 day simple moving average of $46.40 and a two-hundred day simple moving average of $43.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period in the previous year, the business posted $0.11 earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International will post 1.22 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Barry D. Quart sold 13,099 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at $22,398,541.44. This trade represents a 52.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 618,124 shares of company stock valued at $31,923,594. 53.48% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KNSA. Amundi bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter worth approximately $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock worth $507,000 after purchasing an additional 1,002 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the last quarter. Creative Planning bought a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth approximately $358,000. Finally, Quantbot Technologies LP bought a new position in shares of Kiniksa Pharmaceuticals International in the second quarter worth approximately $43,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.